Robert Ragusa Sells 980 Shares of GRAIL (NASDAQ:GRAL) Stock

GRAIL, Inc. (NASDAQ:GRAL) CEO Robert Ragusa sold 980 shares of the stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $53.01, for a total value of $51,949.80. Following the sale, the chief executive officer owned 649,545 shares in the company, valued at approximately $34,432,380.45. This represents a 0.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

GRAIL Price Performance

Shares of GRAIL stock traded down $0.41 during trading hours on Monday, reaching $49.82. The company had a trading volume of 1,587,964 shares, compared to its average volume of 2,112,505. The firm has a market cap of $1.94 billion, a PE ratio of -4.46 and a beta of 5.21. GRAIL, Inc. has a one year low of $20.44 and a one year high of $118.84. The business has a fifty day simple moving average of $88.14 and a 200 day simple moving average of $77.99.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings data on Thursday, February 19th. The company reported ($2.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.33) by $0.89. The company had revenue of $43.60 million for the quarter, compared to analyst estimates of $43.33 million. GRAIL had a negative return on equity of 17.58% and a negative net margin of 277.46%. On average, research analysts forecast that GRAIL, Inc. will post -15.15 EPS for the current year.

Institutional Investors Weigh In On GRAIL

Several hedge funds have recently added to or reduced their stakes in the company. Farallon Capital Management LLC increased its position in shares of GRAIL by 73.7% during the 4th quarter. Farallon Capital Management LLC now owns 2,342,684 shares of the company’s stock valued at $200,510,000 after purchasing an additional 993,684 shares during the last quarter. Baker BROS. Advisors LP grew its position in GRAIL by 27.9% during the fourth quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company’s stock valued at $178,484,000 after acquiring an additional 455,208 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of GRAIL by 9.0% during the fourth quarter. Vanguard Group Inc. now owns 1,980,783 shares of the company’s stock worth $169,535,000 after acquiring an additional 163,790 shares in the last quarter. State Street Corp lifted its holdings in shares of GRAIL by 38.8% in the 4th quarter. State Street Corp now owns 1,827,523 shares of the company’s stock worth $156,418,000 after acquiring an additional 510,546 shares during the last quarter. Finally, Morgan Stanley boosted its stake in shares of GRAIL by 63.8% in the 4th quarter. Morgan Stanley now owns 1,511,687 shares of the company’s stock valued at $129,385,000 after purchasing an additional 588,647 shares in the last quarter.

Analyst Ratings Changes

GRAL has been the topic of several analyst reports. Morgan Stanley lowered their price target on shares of GRAIL from $110.00 to $60.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 24th. Canaccord Genuity Group reduced their price objective on shares of GRAIL from $105.00 to $80.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a report on Thursday, January 22nd. Guggenheim increased their target price on shares of GRAIL from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, Robert W. Baird set a $82.00 price target on shares of GRAIL in a research report on Friday, February 20th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $90.17.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.